260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676
https://vincerx.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 42
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman & CEO | 657.54k | N/A | 1965 |
Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, COO, Secretary & Director | 591.54k | N/A | 1970 |
Mr. Alexander A. Seelenberger M.B.A. | Chief Financial Officer | 491.69k | N/A | 1979 |
Mr. Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer | 444.14k | N/A | 1960 |
Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board | N/A | N/A | N/A |
Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Gabriela Jairala | Sr Executive Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Karen Quarford | Vice President of Quality Operations & Compliance | N/A | N/A | N/A |
Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | N/A | N/A | N/A |
Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | N/A | N/A | N/A |
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Vincerx Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.